A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?

Clinical Rheumatology

Volumn 35, Issue 8, 2016, Pages 2117-2123

  Dall’Ara, Francesca ^a,b,c   Frassi, Micol ^a   Tincani, Angela ^a,c   Airò, Paolo ^a  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Adult onset Still s disease; Autoinflammatory diseases; Biological disease modifying anti rheumatic drugs; Pericarditis

Indexed keywords

ADALIMUMAB; BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT;

ADULT; ADULT ONSET STILL DISEASE; ADVERSE OUTCOME; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD REVIEW; PERICARDITIS; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SKIN MANIFESTATION; SURVIVAL; TREATMENT OUTCOME; COMPLICATION; ITALY; MIDDLE AGED; PROGNOSIS; STILL'S DISEASE, ADULT-ONSET; YOUNG ADULT;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PERICARDITIS; PROGNOSIS; RETROSPECTIVE STUDIES; STILL'S DISEASE, ADULT-ONSET; YOUNG ADULT;

EID: 84954317290     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-3164-y     Document Type: Article

References (25)

1. Efthimiou P, Paik PK, Bielory L (2006) Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis 65:564–572
2. Fautrel B (2008) Adult-onset Still disease. Best Pract Res Clin Rheumatol 22:773–792
3. Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668
4. Rossi-Semerano L, Koné-Paut I (2012) Is Still’s disease an autoinflammatory syndrome? Int J Inflam 2012:480373
5. Rigante D, Cantarini L (2014) The systemic-onset variant of juvenile idiopathic arthritis needs to be recorded as an autoinflammatory syndrome: comment on the review by Nigrovic. Arthritis Rheumatol 66:2645
6. Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P (2014) Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13:1149–1159
7. Cavalli G, Franchini S, Aiello P et al (2015) Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol 44:309–314
8. Kadavath S, Efthimiou P (2015) Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med 47:6–14
9. Yamaguchi M, Ohta A, Tsunematsu T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430
10. Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N (2010) Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol 37:2369–2376
11. Quartuccio L, Salvin S, Zuliani F, Mansutti E, De Vita S (2012) Pleuritis is a red flag for adult-onset Still’s disease which may require biologic therapies. Clin Exp Rheumatol 30:807
12. Henter JI, Horne A, Aricó M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131
13. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG (2010) Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum 62:2530–2535
14. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V et al (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 66:1659–1665
15. Nordström D, Knight A, Luukkainen R et al (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol 39:2008–2011
16. Colafrancesco S, Priori R, Valesini G (2015) Presentation and diagnosis of adult-onset Still’s disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev Clin Immunol 11:749–761
17. Parvez N, Carpenter JL (2009) Cardiac tamponade in Still disease: a review of the literature. South Med J 102:832–837
18. Cantarini L, Lopalco G, Selmi C et al (2015) Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmun Rev 14:90–97
19. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA (2005) Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 52:1794–1803
20. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN (2007) Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66:842–843
21. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L et al (2015) Efficacy of anakinra in refractory adult-onset Still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore) 94(39):e1554
22. Giampietro C, Ridene M, Lequerre T et al (2013) Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken) 65:822–826
23. Hong D, Yang Z, Han S et al (2014) Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther 8:2345–2357
24. Puechal X, deBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O et al (2011) Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken) 63:155–159
25. De Boysson H, Fevrier J, Nicolle A, Auzary C, Geffray L (2013) Tocilizumab in the treatment of the adult-onset Still’s disease: current clinical evidence. Clin Rheumatol 32:141–147